351 related articles for article (PubMed ID: 31873746)
1. Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults.
Letendre SL; Mills A; Hagins D; Swindells S; Felizarta F; Devente J; Bettacchi C; Lou Y; Ford S; Sutton K; Shaik JS; Crauwels H; D'Amico R; Patel P
J Antimicrob Chemother; 2020 Mar; 75(3):648-655. PubMed ID: 31873746
[TBL] [Abstract][Full Text] [Related]
2. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Margolis DA; Gonzalez-Garcia J; Stellbrink HJ; Eron JJ; Yazdanpanah Y; Podzamczer D; Lutz T; Angel JB; Richmond GJ; Clotet B; Gutierrez F; Sloan L; Clair MS; Murray M; Ford SL; Mrus J; Patel P; Crauwels H; Griffith SK; Sutton KC; Dorey D; Smith KY; Williams PE; Spreen WR
Lancet; 2017 Sep; 390(10101):1499-1510. PubMed ID: 28750935
[TBL] [Abstract][Full Text] [Related]
3. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
Chounta V; Overton ET; Mills A; Swindells S; Benn PD; Vanveggel S; van Solingen-Ristea R; Wang Y; Hudson KJ; Shaefer MS; Margolis DA; Smith KY; Spreen WR
Patient; 2021 Nov; 14(6):849-862. PubMed ID: 34056699
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study.
Smith GHR; Henry WK; Podzamczer D; Masiá MDM; Bettacchi CJ; Arasteh K; Jaeger H; Khuong-Josses MA; Montes-Ramírez ML; Stellbrink HJ; Yazdanpanah Y; Richmond GJ; Sutton KC; Zhang F; McCoig CC; St Clair MH; Vandermeulen K; Van Solingen-Ristea R; Smith KY; Margolis DA; Spreen WR
Open Forum Infect Dis; 2021 Sep; 8(9):ofab439. PubMed ID: 34557563
[TBL] [Abstract][Full Text] [Related]
5. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Jaeger H; Overton ET; Richmond G; Rizzardini G; Andrade-Villanueva JF; Mngqibisa R; Hermida AO; Thalme A; Belonosova E; Ajana F; Benn PD; Wang Y; Hudson KJ; Español CM; Ford SL; Crauwels H; Margolis DA; Talarico CL; Smith KY; van Eygen V; Van Solingen-Ristea R; Vanveggel S; Spreen WR
Lancet HIV; 2021 Nov; 8(11):e679-e689. PubMed ID: 34648734
[TBL] [Abstract][Full Text] [Related]
6. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
Orkin C; Oka S; Philibert P; Brinson C; Bassa A; Gusev D; Degen O; García JG; Morell EB; Tan DHS; D'Amico R; Dorey D; Griffith S; Thiagarajah S; St Clair M; Van Solingen-Ristea R; Crauwels H; Ford SL; Patel P; Chounta V; Vanveggel S; Cutrell A; Van Eygen V; Vandermeulen K; Margolis DA; Smith KY; Spreen WR
Lancet HIV; 2021 Apr; 8(4):e185-e196. PubMed ID: 33794181
[TBL] [Abstract][Full Text] [Related]
7. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
Orkin C; Bernal Morell E; Tan DHS; Katner H; Stellbrink HJ; Belonosova E; DeMoor R; Griffith S; Thiagarajah S; Van Solingen-Ristea R; Ford SL; Crauwels H; Patel P; Cutrell A; Smith KY; Vandermeulen K; Birmingham E; St Clair M; Spreen WR; D'Amico R
Lancet HIV; 2021 Nov; 8(11):e668-e678. PubMed ID: 34656207
[TBL] [Abstract][Full Text] [Related]
8. Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
Overton ET; Richmond G; Rizzardini G; Thalme A; Girard PM; Wong A; Porteiro N; Swindells S; Reynes J; Noe S; Harrington C; Español CM; Acuipil C; Aksar A; Wang Y; Ford SL; Crauwels H; van Eygen V; Van Solingen-Ristea R; Latham CL; Thiagarajah S; D'Amico R; Smith KY; Vandermeulen K; Spreen WR
Clin Infect Dis; 2023 May; 76(9):1646-1654. PubMed ID: 36660819
[TBL] [Abstract][Full Text] [Related]
9. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Overton ET; Richmond G; Rizzardini G; Jaeger H; Orrell C; Nagimova F; Bredeek F; García Deltoro M; Swindells S; Andrade-Villanueva JF; Wong A; Khuong-Josses MA; Van Solingen-Ristea R; van Eygen V; Crauwels H; Ford S; Talarico C; Benn P; Wang Y; Hudson KJ; Chounta V; Cutrell A; Patel P; Shaefer M; Margolis DA; Smith KY; Vanveggel S; Spreen W
Lancet; 2021 Dec; 396(10267):1994-2005. PubMed ID: 33308425
[TBL] [Abstract][Full Text] [Related]
10. Asian participants' experience in phase 3/3b studies of long-acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96.
Oka S; Holohan V; Shirasaka T; Choi JY; Kim YS; Chamay N; Patel P; Polli JW; Ford SL; Crauwels H; Garside L; D'Amico R; Latham C; van Solingen-Ristea R; Baugh B; van Wyk J
HIV Med; 2024 Mar; 25(3):381-390. PubMed ID: 38147871
[TBL] [Abstract][Full Text] [Related]
11. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR;
Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299
[TBL] [Abstract][Full Text] [Related]
12. Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.
Gaur AH; Capparelli EV; Calabrese K; Baltrusaitis K; Marzinke MA; McCoig C; Van Solingen-Ristea RM; Mathiba SR; Adeyeye A; Moye JH; Heckman B; Lowenthal ED; Ward S; Milligan R; Samson P; Best BM; Harrington CM; Ford SL; Huang J; Crauwels H; Vandermeulen K; Agwu AL; Smith-Anderson C; Camacho-Gonzalez A; Ounchanum P; Kneebone JL; Townley E; Bolton Moore C; ;
Lancet HIV; 2024 Apr; 11(4):e211-e221. PubMed ID: 38538160
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study.
Murray M; Pulido F; Mills A; Ramgopal M; LeBlanc R; Jaeger H; Canon V; Dorey D; Griffith S; Mrus J; Spreen W; Margolis D
HIV Res Clin Pract; 2019; 20(4-5):111-122. PubMed ID: 31533539
[No Abstract] [Full Text] [Related]
14. Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study.
Garris CP; Czarnogorski M; Dalessandro M; D'Amico R; Nwafor T; Williams W; Merrill D; Wang Y; Stassek L; Wohlfeiler MB; Sinclair GI; Mena LA; Thedinger B; Flamm JA; Benson P; Spreen WR
J Int AIDS Soc; 2022 Sep; 25(9):e26006. PubMed ID: 36097674
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the
Han K; Gevorkyan H; Sadik Shaik J; Crauwels H; Leemereise C; Bontempo G; Win B; Chounta V; Seal C; DeMoor R; D'Amico R; Spreen WR; Ford SL
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0078123. PubMed ID: 38038460
[TBL] [Abstract][Full Text] [Related]
16. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
[TBL] [Abstract][Full Text] [Related]
17. Cabotegravir: a novel HIV integrase inhibitor combined with rilpivirine as the first long-acting injectable program for the treatment of HIV infection.
Zeuli JD; Rivera CG; Smith BL; Otto A; Temesgen Z
Drugs Today (Barc); 2022 Dec; 58(12):555-576. PubMed ID: 36651065
[TBL] [Abstract][Full Text] [Related]
18. Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy.
D'Amico R; Cenoz Gomis S; Moodley R; Van Solingen-Ristea R; Baugh B; Van Landuyt E; Van Eygen V; Min S; Cutrell A; Foster C; Chilton D; Allard SD; Ruiter A
HIV Med; 2023 Feb; 24(2):202-211. PubMed ID: 35945163
[TBL] [Abstract][Full Text] [Related]
19. Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
Rizzardini G; Overton ET; Orkin C; Swindells S; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Girard PM; Oka S; Andrade-Villanueva JF; Richmond GJ; Baumgarten A; Masiá M; Latiff G; Griffith S; Harrington CM; Hudson KJ; St Clair M; Talarico CL; Patel P; Cutrell A; Van Eygen V; D'Amico R; Mrus JM; Wu S; Ford SL; Chow K; Roberts J; Wills A; Walters N; Vanveggel S; Van Solingen-Ristea R; Crauwels H; Smith KY; Spreen WR; Margolis DA
J Acquir Immune Defic Syndr; 2020 Dec; 85(4):498-506. PubMed ID: 33136751
[TBL] [Abstract][Full Text] [Related]
20. Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy.
Mills A; Richmond GJ; Newman C; Osiyemi O; Cade J; Brinson C; De Vente J; Margolis DA; Sutton KC; Wilches V; Hatch S; Roberts J; McCoig C; Garris C; Vandermeulen K; Spreen WR
AIDS; 2022 Feb; 36(2):195-203. PubMed ID: 34652287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
